Diabetes News

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, presents updated multispecialty practice recommendations for diabetes, cardiorenal and metabolic diseases at the Heart in Diabetes CME Conference.

Multidisciplinary experts from across cardiometabolic subspecialties will gather again to showcase the latest clinical research at the Heart in Diabetes CME Conference.

Due to demographic changes and a rise in risk factors, the prevalence and economic burden of heart disease and stroke in the United States are expected to increase dramatically by 2050, according to the American Heart Association.

Consuming more flavonoids and flavonoid-rich foods such as tea, berries and apples was associated with a lower risk for type 2 diabetes, researchers found.

The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more.

Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.

Dispensing of GLP-1 receptor agonists increased nearly 600% among adolescents and young adults in the United States from 2020 to 2023 and was particularly significant among girls and young women, a new study showed.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

Individuals prescribed the antidiabetes treatment metformin less likely developed a myeloproliferative neoplasm —potentially also reducing a person’s chances for developing certain cancers — according to data published in Blood Advances.

In patients with type 2 diabetes who underwent ablation for atrial fibrillation, those taking a GLP-1 receptor agonist had lower risk for AF recurrence, mortality and other outcomes, researchers reported at Heart Rhythm 2024.